海利生物
(603718)
| 流通市值：46.73亿 | | | 总市值：47.21亿 |
| 流通股本：6.49亿 | | | 总股本：6.56亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 109,776,927.64 | 61,792,980.19 | 271,039,818.26 | 174,428,026.55 |
| 营业收入 | 109,776,927.64 | 61,792,980.19 | 271,039,818.26 | 174,428,026.55 |
| 二、营业总成本 | 76,009,089.52 | 41,355,751.57 | 241,171,112.08 | 210,114,237.84 |
| 营业成本 | 25,125,479.07 | 14,854,132.26 | 107,861,963.96 | 88,818,920.59 |
| 税金及附加 | 987,951.12 | 450,713.31 | 3,915,313.05 | 2,273,480.53 |
| 销售费用 | 20,406,702.4 | 10,373,489.06 | 49,329,513.58 | 35,785,269.02 |
| 管理费用 | 20,112,692.25 | 11,291,949.78 | 62,623,479.47 | 62,962,578.79 |
| 研发费用 | 12,163,351.77 | 6,040,598.06 | 24,454,326.46 | 16,830,160.27 |
| 财务费用 | -2,787,087.09 | -1,655,130.9 | -7,013,484.44 | 3,443,828.64 |
| 其中:利息费用 | 772,082.74 | - | 5,490,985.78 | 3,821,868.26 |
| 其中:利息收入 | 4,271,680.41 | 2,145,710.13 | 2,206,066.33 | 412,700.61 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,501,099.14 | 429,155.48 | -12,761,890.33 | -848,057.4 |
| 加:投资收益 | 223,930.93 | 284,477.72 | 158,406,545.28 | 7,675,102.94 |
| 资产处置收益 | 223,211.51 | - | - | - |
| 资产减值损失(新) | - | - | -3,714,782.36 | - |
| 信用减值损失(新) | -694,816.64 | -1,562,628.63 | -3,938,168.64 | -2,169,615.69 |
| 其他收益 | 1,633,461.06 | 1,340,545.04 | 6,665,886.94 | 3,615,546.28 |
| 四、营业利润 | 36,654,724.12 | 20,928,778.23 | 174,526,297.07 | -27,413,235.16 |
| 加:营业外收入 | 64,225.65 | 64,224.89 | 34,337,569.37 | 34,780,874.15 |
| 减:营业外支出 | 122,375.17 | 1,997.54 | 746,410.66 | 90,369.35 |
| 五、利润总额 | 36,596,574.6 | 20,991,005.58 | 208,117,455.78 | 7,277,269.64 |
| 减:所得税费用 | 4,617,231.84 | 3,053,679.42 | 26,481,859.77 | -8,131,720.34 |
| 六、净利润 | 31,979,342.76 | 17,937,326.16 | 181,635,596.01 | 15,408,989.98 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 31,979,342.76 | 17,937,326.16 | 181,635,596.01 | 15,408,989.98 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 18,234,848.34 | 10,901,715.1 | 171,180,295.61 | 20,173,396.25 |
| 少数股东损益 | 13,744,494.42 | 7,035,611.06 | 10,455,300.4 | -4,764,406.27 |
| 扣除非经常损益后的净利润 | 15,469,536.74 | 9,199,267.3 | 10,581,377.63 | -4,438,854.5 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0.02 | 0.27 | 0.03 |
| (二)稀释每股收益 | 0.03 | 0.02 | 0.26 | 0.03 |
| 八、其他综合收益 | - | - | 2,571,231.12 | 1,568,638.59 |
| 归属于母公司股东的其他综合收益 | - | - | 2,571,231.12 | 1,568,638.59 |
| 九、综合收益总额 | 31,979,342.76 | 17,937,326.16 | 184,206,827.13 | 16,977,628.57 |
| 归属于母公司股东的综合收益总额 | 18,234,848.34 | 10,901,715.1 | 173,751,526.73 | 21,742,034.84 |
| 归属于少数股东的综合收益总额 | 13,744,494.42 | 7,035,611.06 | 10,455,300.4 | -4,764,406.27 |
| 公告日期 | 2025-08-28 | 2025-04-22 | 2025-04-22 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |